Beta Bionics, Inc. BBNX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -72.97M | -66.44M | -73.20M | -77.84M | -73.37M |
| Total Depreciation and Amortization | 3.72M | 3.26M | 2.88M | 2.47M | 2.40M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.16M | 19.13M | 28.39M | 29.33M | 26.06M |
| Change in Net Operating Assets | -8.72M | -10.73M | -8.99M | -10.53M | -12.55M |
| Cash from Operations | -55.81M | -54.78M | -50.93M | -56.58M | -57.46M |
| Capital Expenditure | -5.60M | -6.34M | -5.30M | -3.96M | -4.59M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 64.52M | 44.50M | -157.51M | -189.17M | -182.78M |
| Cash from Investing | 58.92M | 38.16M | -162.81M | -193.13M | -187.37M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6.14M | 4.38M | 214.87M | 213.85M | 211.25M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 59.66M | 59.66M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -2.81M | -4.03M |
| Cash from Financing | 6.14M | 4.38M | 214.87M | 270.71M | 266.88M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.24M | -12.25M | 1.14M | 21.00M | 22.05M |